Preliminary study on human papilloma virus 16 and Epstein-Barr virus infections in breast cancer patients

doi:10.3877/cma. j. issn.1674-0807.2014.05.003

Abstract

Abstract:

Objective

To explore the expression of human papilloma virus 16 (HPV16) and Epstein-Barr virus(EBV)in different pathological types of breast cancer and breast benign lesions.

Methods

We analyzed the samples from 90 cases of different pathological types of breast cancer (including 40 cases of invasive ductal carcinoma, 30 invasive lobular carcinoma and 20 carcinoma in situ), 20 cases of mammary fibroma and 10 cases of normal breast tissues. All specimens were collected from the patients treated in our hospital from June 2013 to June 2014. PCR was performed to amplify E6 gene site of HPV16 and the repeated sequence BamHIW of EBV. The expressions of HPV16 and latent membrane protein 1 (LMP-1) of EBV were detected by immunohistochemical staining to determine whether existed HPV16 or EBV infections, and the positive rate was calculated accordingly. The detection rate of virus between different pathological types of breast cancer and the detection rate of virus between PCR detection and immunohistochemistry was compared by χ² test;the proportion of HPV16 positive cells and the proportion of EBV positive cells among different pathological types of breast cancer was compared by analysis of variance and Bonferroni pairwise comparison.

Results

PCR showed that HPV16 detection rate was 44.44% (40/90) in breast cancer, 5% (1/20) in mammary fibroma and 0 in normal breast tissues; EBV detection rate was 43.33% (39/90) in breast cancer, 0 in mammary fibroma and normal breast tissues; there were no statistically significant difference in the detection rate of HPV16 and EBV between different pathological types of breast cancer (χ²= 1.238, P=0.539; χ²= 1.867,P=0.393). Immunohistochemistry showed that HPV16 detection rate was 42.22% (38/90) in breast cancer,5% (1/20) in mammary fibroma and 0 in normal breast tissues; EBV detection rate was 42.22%(38/90)in breast cancer, 0 in mammary fibroma and normal breast tissues. The proportion of HPV16 positive cells was(29.78±0.38)% in invasive ductal carcinoma, (28.31±0.53)% in invasive lobular carcinoma, (51.83±0.65)% in carcinoma in situ, suggesting a significant difference (F=537.779, P=0.000). The proportion of EBV positive cells was (29.73±0.51)%, (28.14±0.65)% and (51.11±0.68)% respectively, which was significantly different (F=427.771, P=0.000); the sample of carcinoma in situ showed the higher proportion of HPV16 and EBV positive cells, compared with other two pathological types(all P=0.000). The detection rates of HPV16 or EBV by PCR and immunohistochemistry in breast cancer specimens were not significantly different (χ²=0.090, P=0.764; χ² =0.023, P=0.880).

Conclusion

The infection of HPV16 and EBV may be related to the occurrence of breast cancer, and the infection degree is probably related to the pathological types of breast cancer.

Key words: Breast neoplasms, Human papilloma virus 16, Epstein-Barr virus

Chenyang He, Ting Wang, Yonggang Lyu, Juliang Zhang, Yongping Li, Ge Zhao, Fucheng Ma, Jiayun Liu, Jianghao Chen, Ling Wang. Preliminary study on human papilloma virus 16 and Epstein-Barr virus infections in breast cancer patients[J]. Chinese Journal of Breast Disease(Electronic Edition), 2014, 08(05): 10-15.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma. j. issn.1674-0807.2014.05.003

https://zhrxbzz.cma-cmc.com.cn/EN/Y2014/V08/I05/10

Figures/Tables 2

References 26

[1]	Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China,2010[J]. Chin J Cancer Res,2014,26(1):48-58.
[2]	Di Lonardo A,Venuti A,Marcante ML. Human papillomavirus in breast cancer[J]. Breast Cancer Res Treat,1992,21(2):95-100.
[3]	de Villiers EM, Sandstrom RE, zur Hausen H, et al. Presence of papillomavirus sequences in condylomatous lesions of the mamillae and in invasive carcinoma of the breast[J]. Breast Cancer Res,2005,7(1):R1-11.
[4]	Lindel K, Forster A, Altermatt HJ, et al. Breast cancer and human papillomavirus (HPV) infection: no evidence of a viral etiology in a group of Swiss women[J]. Breast,2007,16(2):172-177.
[5]	de Cremoux P, Thioux M, Lebigot I, et al. No evidence of human papillomavirus DNA sequences in invasive breast carcinoma[J]. Breast Cancer Res Treat,2008,109(1):55-58.
[6]	Glenn WK, Heng B, Delprado W, et al. Epstein-Barr virus,human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer [J]. PLoS One, 2012,7(11):e48788.
[7]	Gaffey MJ, Frierson HF Jr, Mills SE, et al. Medullary carcinoma of the breast. Identification of lymphocyte subpopulations and their significance[J]. Mod Pathol,1993,6(6):721-728.
[8]	Hanning JE, Groves IJ, Pett MR, et al. Depletion of polycistronic transcripts using short interfering RNAs: cDNA synthesis method affects levels of non-targeted genes determined by quantitative PCR[J]. Virol J,2013,10:159.
[9]	Jones MD, Griffin BE. Clustered repeat sequences in the genome of Epstein Barr virus[J]. Nucleic Acids Res, 1983,11(12):3919-3937.
[10]	Becerik S, Ozsan N, Gürkan A, et al. Toll like receptor 4 and membrane-bound CD14 expressions in gingivitis, periodontitis and CsA-induced gingival overgrowth[J]. Arch Oral Biol,2011,56(5):456-465.
[11]	Hedau S, Kumar U, Hussain S, et al. Breast cancer and human papillomavirus infection: no evidence of HPV etiology of breast cancer in Indian women[J]. BMC Cancer, 2011,11:27.
[12]	Herrera-Goepfert R, Vela-Chávez T, Carrillo-García A, et al.High-risk human papillomavirus (HPV) DNA sequences in metaplastic breast carcinomas of Mexican women[J]. BMC Cancer,2013,13:445.
[13]	Khan NA, Castillo A, Koriyama C, et al. Human papillomavirus detected in female breast carcinomas in Japan[J]. Br J Cancer,2008,99(3):408-414.
[14]	Horiuchi K, Mishima K, Ohsawa M, et al. Carcinoma of stomach and breast with lymphoid stroma: localisation of Epstein-Barr virus[J]. J Clin Pathol,1994,47(6):538-540.
[15]	Yahia ZA,Adam AA,Elgizouli M,et al. Epstein Barr virus:a prime candidate of breast cancer aetiology in Sudanese patients[J]. Infect Agent Cancer,2014,9(1):9.
[16]	Zekri AR, Bahnassy AA, Mohamed WS, et al. Epstein-Barr virus and breast cancer:epidemiological and molecular study on Egyptian and Iraqi women[J]. J Egypt Natl Canc Inst, 2012,24(3):123-131.
[17]	Morales-Sánchez A, Molina-Muñoz T, Martínez-López JL, et al. No association between Epstein-Barr Virus and Mouse Mammary Tumor Virus with breast cancer in Mexican women[J]. Sci Rep,2013,3:2970.
[18]	Hennig EM, Kvinnsland S, Holm R, et al. Significant difference in p53 and p21 protein immunoreactivity in HPV 16 positive and HPV negative breast carcinomas[J]. Acta Oncol,1999,38(7):931-938.
[19]	Damin AP, Karam R, Zettler CG, et al. Evidence for an association of human papillomavirus and breast carcinomas[J].Breast Cancer Res Treat,2004,84(2):131-137.
[20]	Kan CY, Iacopetta BJ, Lawson JS, et al. Identification of human papillomavirus DNA gene sequences in human breast cancer[J]. Br J Cancer,2005,93(8):946-948.
[21]	Hagensee ME, Herrel N, D'Angelo A, et al. Epstein Barr virus interacts with human papilloma virus to decrease apoptosis in vitroand increase cervical dysplasia in vivo/ /International Centre Genetic Engineering Biotechnology DNA Tumor Virus Meeting Proceedings. Trieste: United Nations Industrial Development Organization,2011.
[22]	杨文涛,许良中,李泰明,等. 102 例乳腺癌中的EB 病毒感染[J]. 上海医科大学学报,1998,25(3):175-178.
[23]	Labrecque LG, Barnes DM, Fentiman IS, et al. Epstein-Barr virus in epithelial cell tumors: a breast cancer study[J].Cancer Res,1995,55(1):39-45.
[24]	Akil N, Kassab A, Yasmeen A, et al. Human breast cancer and sexual activities[J]. Br J Cancer, 2008, 98(2):508-511.
[25]	Troeltzsch M, Knösel T, Eichinger C, et al. Clinicopathologic features of oral squamous cell carcinoma: do they vary in different age groups? [J]. J Oral Maxillofac Surg, 2014,72(7):1291-1300.
[26]	Chu PG, Chang KL, Chen YY, et al. No significant association of Epstein-Barr virus infection with invasive breast carcinoma[J]. Am J Pathol,2001,159(2):571-578.

病理类型	例数	HPV16(例)		检出率(%)	χ ²值	P值
病理类型	例数	+	-	检出率(%)	χ ²值	P值
浸润性导管癌	40	20	20	50.00	1.238	0.539
浸润性小叶癌	30	11	19	36.67
原位癌	20	9	11	45.00
合计	90	40	50	44.44

病理类型	例数	HPV16(例)		检出率(%)	χ ²值	P值
病理类型	例数	+	-	检出率(%)	χ ²值	P值
浸润性导管癌	40	20	20	50.00	1.238	0.539
浸润性小叶癌	30	11	19	36.67
原位癌	20	9	11	45.00
合计	90	40	50	44.44

病理类型	例数	EBV(例)		检出率(%)	χ ²值	P值
病理类型	例数	+	-	检出率(%)	χ ²值	P值
浸润性导管癌	40	19	21	47.50	1.867	0.393
浸润性小叶癌	30	10	20	33.33
原位癌	20	10	10	50.00
合计	90	39	51	43.33

病理类型	例数	EBV(例)		检出率(%)	χ ²值	P值
病理类型	例数	+	-	检出率(%)	χ ²值	P值
浸润性导管癌	40	19	21	47.50	1.867	0.393
浸润性小叶癌	30	10	20	33.33
原位癌	20	10	10	50.00
合计	90	39	51	43.33

Please choose a citation manager

Content to export